Several clinical trials have been conducted to examine the efficacy of SGLT-2 inhibitors in patients with MASLD and T2DM, and the results has indicated that SGLT-2 inhibitors (canagliflozin, dapagliflozin or empagliflozin) significantly improves hepatic lipid deposition, liver enzyme levels and liver stiffness [61–65]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.